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Lentiviral (LV) vectors can transduce slowly dividing cells such as those of the
airway epithelium, the recognised target of CF lung disease. However, efﬁcient
LV-mediated transduction of airway epithelial cells is hampered by extra-cellular
barriers. Thus, the local conﬁnement on the cell surface of LV vectors is an
important requirement for gene delivery to the airway epithelium.
To address this issue we have exploited the magnetofection technique in in vitro
models of airway epithelium applying a LV vector carrying the Green Fluorescent
Protein (GFP) gene. Magnetofectins were formed by non-covalent interaction
between LV particles and polycation-coated iron oxide nanoparticles. Bronchial
16HBE14o- and bronchiolar H441 cells were tranduced with magnetofectins in
the presence of a magnetic ﬁeld. Magnetofectins were more efﬁcient than LV
alone up to 3.9 fold and magnetofection was able to signiﬁcantly increase the
percentage of transduced cells already after 15 minutes of incubation. We next
asked whether magnetofection could also be efﬁcient in polarised 16HBE14o-
cells. Magnetofection determined a 3-fold increase of GFP+ cells (up to 10%) as
compared with LV alone. Upon treatment with 50 nM dexamethasone, H441 cells
can form hemicysts containing ﬂuid, called “domes”, which are relatively resistant
to LV-mediated transduction (GFP+ cells = 6%). Magnetofection increased up to
4 fold the transduction efﬁciency. Conversely, in the absence of magnetic ﬁeld no
signiﬁcant effect could be observed. We conclude that magnetofection can facilitate
LV-mediated transduction of airway epithelial cells by lowering vector dose and
reducing incubation time to achieve efﬁcient transduction.
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The feasibility of using gene therapy to treat CF lung disease has been investigated
in the clinic with a variety of gene transfer agents. It is anticipated that treatments
aimed at preventing or delaying loss of lung function should be undertaken as
early as possible and therefore in utero gene therapy has been suggested as one
approach to prevent the onset of disease symptoms in childhood. This approach has
many problems, but it also has the potential for improved gene transfer efﬁciency
due to the accessibility of expanding target cell populations in rapidly developing
organs and the reduced immune recognition of the vector. In addition this approach
could also compensate for any role that CFTR plays in the developing organs and
previously published studies (Larson et al Lancet 349:619) showed that transient
expression of human CFTR in utero was sufﬁcient to rescue the fatal intestinal
defect in S489X Cftrtm1Unc/Cftrtm1Unc knockout mice. We replicated these studies
using an identical CFTR-expressing adenoviral vector and CF mouse strain in
sufﬁciently large numbers to provide robust Kaplan–Meier survival data. Although
each step of the procedure was carefully controlled and vector-speciﬁc CFTR
mRNA expression was conﬁrmed in the fetal organs after treatment, we observed
no statistically signiﬁcant improvement in the survival of mice treated in utero
compared with contemporaneous control treated animals.
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Rationale: CF results from a nonsense (premature stop codon) mutation in ~10% of
cases. PTC124 is an oral, small-molecule drug that induces ribosomal readthrough
of premature stop codons in CFTR mRNA to induce production of full-length,
functional protein. This Phase 2a clinical trial is evaluating PTC124 in children
with nonsense-mutation-mediated CF.
Methods: In a crossover design, patients 6−18 years of age receive two 14-day
courses of PTC124 with dose-level sequence assigned randomly (low-high or high-
low). Assessments include nasal epithelial CFTR protein by immunoﬂuorescence,
total chloride conductance by NPD, and PK.
Results: Data are available for 11 patients (6M:5F with median [range] age =
15 [7−18] years; median [range] % predicted FEV1 = 90 [41–151]; % Pseudomonas
infection = 3/11 [27%]; pancreatic insufﬁciency = 11/11 [100%]). G542X and
W1282X were the most common mutation types. In 4 evaluable patients, PTC124
induced full-length, apically localized epithelial CFTR in 58% of nasal ciliated cells.
NPD total chloride conductance improved signiﬁcantly across both low and high
doses. Total chloride conductance normalized to 5mV in 6/11 (55%) of patients,
with improvements in multiple mutation types. Adverse events and laboratory
abnormalities were generally mild. PK parameters were similar to those observed
in adults.
Conclusions: PTC124 shows pharmacodynamic activity and acceptable tolerability
in children with nonsense-mutation-mediated CF. Accrual is ongoing.
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CF results from nonsense mutations in the mRNA for the CFTR in ~10% of patients
worldwide and >50% of patients in Israel. PTC124 is an orally administered,
small-molecule investigational drug that induces ribosomal readthrough of nonsense
mutations, restoring full-length protein production.
Patients with nonsense-mutation-mediated CF completing two 2-week courses of
PTC124 in a prior Phase 2a study were eligible for this 12-week extension. Patients
received PTC124 at respective morning, mid-day, and evening doses of either 4,
4, and 8mg/kg or 10, 10, and 20mg/kg based on their response in the Phase 2a
study. Assessments included total chloride conductance by NPD, FEV1 and FVC
by spirometry, and cough frequency via the VivoMetrics Lifeshirt®.
Patients were 19 adults not in CF exacerbation (males:females = 10:9; me-
dian [range] age = 27 [19−57] years; median [range] % predicted FEV1 and
FVC =65 [44–106]% and 80 [58–112]%; Pseudomonas airway colonization = 17/19
[89%]; exocrine pancreatic insufﬁciency = 17/19 [89%]). Both dosing regimens
showed statistically signiﬁcant improvements in NPD chloride conductance over
baseline as well as in the proportion of patients normalized to 5mV. PTC124
was associated with increases in pulmonary function and statistically signiﬁcant
decreases in cough frequency. Effects improved with longer duration of treatment.
Adverse events were mostly mild, not clearly dose-dependent, and not clinically
signiﬁcant.
PTC124 shows activity and acceptable tolerability when given long-term. These
data support initiation of a larger, placebo-controlled Phase 2b trial of PTC124 in
CF.
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